# Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

> **NCT00670748** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Metastatic Melanoma
- Metastatic Renal Cell Cancer
- Metastatic Cancer

## Interventions

- **BIOLOGICAL:** Anti-NY ESO-1 T-cell receptor PBL
- **DRUG:** aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** fludarabine phosphate
- **BIOLOGICAL:** ALVAC NY ESO-1 vaccine

## Key facts

- **NCT ID:** NCT00670748
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05-29
- **Primary completion:** 2016-06-29
- **Final completion:** 2016-06-29
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** A more highly selected protocol with ESO TCR opened for pts with melanoma
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00670748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00670748, "Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00670748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*